Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential

[1]  T. Ørntoft,et al.  Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. , 2014, European urology.

[2]  E. Zwarthoff,et al.  Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. , 2013, The Journal of urology.

[3]  M. Zeegers,et al.  Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma , 2013, British Journal of Cancer.

[4]  S. Pongor,et al.  Jagged-1 juxtamembrane region: biochemical characterization and cleavage by ADAM17 (TACE) catalytic domain. , 2013, Biochemical and biophysical research communications.

[5]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[6]  B. Mack,et al.  EpCAM regulates cell cycle progression via control of cyclin D1 expression , 2013, Oncogene.

[7]  S. Goodison,et al.  Urinary BTA: indicator of bladder cancer or of hematuria , 2012, World Journal of Urology.

[8]  S. Goodison,et al.  Influencing factors on the NMP-22 urine assay: an experimental model , 2012, BMC Urology.

[9]  F. Hamdy,et al.  An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer , 2012, British Journal of Cancer.

[10]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[11]  A. Kibel,et al.  Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[12]  J. Witjes,et al.  [Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. , 2012, Actas urologicas espanolas.

[13]  T. Todenhöfer,et al.  Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria , 2011, Advances in urology.

[14]  H. Grossman,et al.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[15]  Carsten Wiuf,et al.  Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.

[16]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. , 2011, European urology.

[17]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[18]  K. Izumi,et al.  Severe Renal Hemorrhage in a Pregnant Woman Complicated with Antiphospholipid Syndrome: A Case Report , 2011, Advances in urology.

[19]  A. Wolf,et al.  Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110 , 2011, mAbs.

[20]  S. S. Chauhan,et al.  Nuclear and Cytoplasmic Accumulation of Ep-ICD Is Frequently Detected in Human Epithelial Cancers , 2010, PloS one.

[21]  J. Cizeau,et al.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients , 2010, Drug design, development and therapy.

[22]  M. Zeegers,et al.  The West Midlands Bladder Cancer Prognosis Programme: rationale and design , 2010, BJU international.

[23]  E. Higashihara,et al.  Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer , 2010, International journal of urology : official journal of the Japanese Urological Association.

[24]  G. Mowatt,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.

[25]  V. Entwistle,et al.  Effectiveness and cost-effectiveness of arthroscopic lavage in the treatment of osteoarthritis of the knee: a mixed methods study of the feasibility of conducting a surgical placebo-controlled trial (the KORAL study). , 2010, Health technology assessment.

[26]  J. Wesseling,et al.  Cell Discohesion and Multifocality of Carcinoma In situ of the Bladder: New Insight From the Adhesion Molecule Profile (e-Cadherin, Ep-CAM, and MUC1) , 2009, International journal of surgical pathology.

[27]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[28]  Brigitte Mack,et al.  Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.

[29]  A. Tzankov,et al.  EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder , 2007, Journal of Clinical Pathology.

[30]  Ahmad Faried,et al.  Prognostic significance of EpCAM expression in human esophageal cancer. , 2007, International journal of oncology.

[31]  M. Kuroki,et al.  Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. , 2002, Journal of immunological methods.

[32]  J. M. Chong,et al.  Determination of Disulfide Bond Assignments andN-Glycosylation Sites of the Human Gastrointestinal Carcinoma Antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM)* , 2001, The Journal of Biological Chemistry.

[33]  S. Szala,et al.  Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.